InvestorsHub Logo
Followers 0
Posts 842
Boards Moderated 0
Alias Born 04/19/2006

Re: opportunityknocking post# 10982

Thursday, 01/10/2008 1:53:16 PM

Thursday, January 10, 2008 1:53:16 PM

Post# of 30387
From the PR:

"BioCurex is a biotechnology company with patented/proprietary technology identifying a cancer marker, RECAF. RECAF (the receptor for alpha-fetoprotein) is a wide-spectrum marker present in malignant cancer cells and absent in most normal cells, allowing it to play a major role in the development of new diagnostic tests for prostate, breast, colorectal, lung and other cancers. More than three years of testing by BioCurex has confirmed RECAF’s high degree of clinical sensitivity and specificity in detecting various types of cancer, even when the disease is at its earliest stage."

They just didn't use the word "Universal", which would be inaccurate anyway. Inaccuracy got them delisted once before.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.